Malaria down but not out (yet)
17 December, 2010 by Tim DeanThe WHO report on malaria shows promising reductions in infections and deaths, but scientists warn malaria might be back with a vengeance unless efforts to eradicate it aren't maintained.
Feature: Antibody attack on acute myeloid leukaemia
16 December, 2010 by Staff WritersCLS Principal Scientist, Samantha Busfield, is working on CSL’s newly developed anti-interleukin-3 (IL3) receptor antibody in the hope that it will provide a new treatment for acute myeloid leukaemia.
LCT gets green light from Russia for Type 1 diabetes treatment Diabecell
10 December, 2010 by David BinningLiving Cell Technologies (LCT) announced today that Russia has become the first country in the world to approve the use and sale of its Diabecell porcine implant for Type 1 diabetics.
Could aspirin help to prevent deaths from cancer, or even cancer itself?
07 December, 2010 by David BinningBritish researchers have published the results of a study which shows that a small dose of aspirin daily could dramatically reduce incidences of cancer related death.
New class of HIV drug in the offing
02 December, 2010 by David BinningAustralian biotech Biotron has reaffirmed its commitment to its HIV drug program following the release of an independent international study demonstrating that the protein Vpu plays a key role in allowing the virus to proliferate.
Feature: Puzzling prions
29 November, 2010 by Fiona WyliePrions, which cause diseases such as Creutzfeldt-Jakob and bovine spongiform encephalopathy (BSE), are mysterious things. Andrew Hill’s research into how they spread might lead to new diagnostics and treatments.
Avexa to discuss HIV drug with FDA
27 November, 2010 by David BinningBeleaguered Australian HIV drug developer Avexa announced this week that it has booked time with the FDA to discuss opportunities for its ATC (apricitibane) program.
Universal flu vaccine in the offing
24 November, 2010 by David BinningCanberra-based biotech Gamma Vaccines reported today that it is ready to start human clinical trials of a universal flu vaccine which it hopes will one day do away with the need for new vaccines to be produced every year while being effective against any pandemic strains.
Infectious diseases targeted by new ithree institute
24 November, 2010 by Staff WritersThe University of Technology Sydney has launched the ithree institute, focusing on the understanding and control of infectious diseases in humans and animals.
Erectile dysfunction linked to higher risk of heart disease
24 November, 2010 by Staff WritersA team of international researchers has published the results of a study showing a connection between erectile dysfunction and increased risk of heart disease.
Feature: Epigenetics and diabetes
23 November, 2010 by Graeme O'NeillThe phenomenon of ‘glycaemic memory’ has long puzzled diabetes clinicians and researchers. Now, researchers at the Baker Heart and International Diabetes Institute (Baker IDI) have made a crucial advance that explains how exposure to high blood-glucose levels drives epigenetic changes that underlie the syndrome.
Novogen reports positive results from U.S cancer study
19 November, 2010 by David BinningShares in Sydney biotech Novogen jumped 16.7 percent today on news that its majority-owned US subsidiary Marshall Edwards had reported positive data from it anti-cancer therapeutic, NV-128.
Feature: The science of longevity: Resveratrol and beyond
19 November, 2010 by Tim DeanSustaining a long, healthy life is the holy grail of medical science. David Sinclair, discoverer of resveratrol, is working on understanding the mechanisms underlying ageing with the hope of producing new drugs that combat diseases and maybe even extend life itself.
Ageing, heart disease and colour blindness among key themes for 5th AHMRC
18 November, 2010 by David BinningThe 5th Australian Health and Medical Research Congress (AHMRC) wound up in Melbourne today after this week playing host to a coterie of top local and international researchers.
Bionomics reports strong data from anxiety and depression study
17 November, 2010 by Staff WritersAdelaide biotech Bionomics has reported positive data from a study of its anti-anxiety and depression drug BNC210, indicating a number of potential advantages over its many blockbuster rivals.
